Evidence map›Paper›PMID 37856046›Full record

ArticleDiabetes therapy : research, treatment and education of diabetes and related disorders2024

Prevalence of Metabolic Syndrome in Patients with Type 2 Diabetes in Japan: A Retrospective Cross-Sectional Study.

Yasushi Ishigaki, Tetsuaki Hirase, Swathi Pathadka, Zhihong Cai, Manaka Sato, Ryo Takemura, Noriyuki Ishida

Abstract read
In one paragraph

Article in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Observational
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yasushi IshigakiDivision of Diabetes, Metabolism, and Endocrinology, Department of Internal Medicine, Iwate Medical University, Yahaba, Japan.ORCID http://orcid.org/0000-0003-2479-5752
Tetsuaki HiraseJapan Drug Development and Medical Affairs, Eli Lilly Japan K.K., Hyogo, Japan.
Swathi PathadkaLilly Capability Center India, Eli Lilly Services Private Ltd, 1st Floor, Building Primrose 7B, Wing B, Embassy Tech Village, Devarabisanahalli, Bengaluru, Karnataka, 560103, India. pathadka_swathi@lilly.com.ORCID http://orcid.org/0000-0002-1793-1800
Zhihong CaiJapan Drug Development and Medical Affairs, Eli Lilly Japan K.K., Hyogo, Japan.ORCID http://orcid.org/0000-0002-3431-197X
Manaka SatoJapan Drug Development and Medical Affairs, Eli Lilly Japan K.K., Hyogo, Japan.ORCID http://orcid.org/0000-0001-7000-4769
Ryo TakemuraBiostatistics Unit, Clinical and Translational Research Center, Keio University Hospital, Tokyo, Japan.
Noriyuki IshidaBiostatistics Unit, Clinical and Translational Research Center, Keio University Hospital, Tokyo, Japan.ORCID http://orcid.org/0000-0003-2826-6567

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionRecent data on the prevalence of metabolic syndrome in Japanese patients with type 2 diabetes (T2D) are limited.

methodsThis retrospective, cross-sectional, observational study investigated the prevalence of metabolic syndrome in patients with T2D using a Japanese administrative claims database. Patients with a T2D diagnosis, prescription of a hypoglycemic agent, and one or more annual health checkups in 2020 were included. Trends in the prevalence of metabolic syndrome by sex and body mass index (BMI) subgroup were assessed.

resultsThe study cohort consisted of 155,653 patients (men, 81.6%; mean age 54.6 ± 8.5 years). Patients with metabolic syndrome had a higher mean BMI (29.1 ± 4.5 kg/m

conclusionThe prevalence of metabolic syndrome in Japanese patients with T2D was 43.0% and increased with higher BMI. In patients with T2D and metabolic syndrome, cardiovascular drug usage and comorbidities increased in patients with a higher BMI. These data highlight the importance of managing metabolic parameters in addition to glycemic control in Japanese patients with T2D, particularly in patients with metabolic syndrome and BMI ≥ 25 kg/m

Indexed as

Body mass indexJapanJapanese administrative claims databaseMetabolic syndromeType 2 diabetesWaist circumference

Identifiers

PMID37856046
PMCPMC10786760

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.